Skip to main
ALZN
ALZN logo

Alzamend Neuro (ALZN) Stock Forecast & Price Target

Alzamend Neuro (ALZN) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alzamend Neuro Inc. has reported positive top-line results from its clinical studies, indicating promising advancements in its therapeutic pipeline for treating neurodegenerative diseases and psychiatric disorders. The company's unique drug candidates, AL001 and AL002, utilize innovative technologies that have potential therapeutic benefits, particularly in combating Alzheimer's disease. With current valuations being considered attractive and anticipated key milestones poised to act as catalysts for growth, there is an optimistic outlook for the company’s future performance in the biopharmaceutical sector.

Bears say

Alzamend Neuro Inc reported a net loss of $2.7 million, equating to an earnings per share (EPS) of $(1.28), which was significantly worse than the estimates of $(0.69). The company faces numerous risks that could impede its financial performance, including balance sheet and liquidity concerns, potential failures in demonstrating the safety and efficacy of its product candidates during clinical trials, and challenges in obtaining regulatory approvals. Additionally, competitive pressures and changing macroeconomic factors may further undermine investor confidence and the overall investment climate for biotech stocks, contributing to the negative outlook on the company's stock.

Alzamend Neuro (ALZN) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alzamend Neuro and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alzamend Neuro (ALZN) Forecast

Analysts have given Alzamend Neuro (ALZN) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Alzamend Neuro (ALZN) has a Strong Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alzamend Neuro (ALZN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.